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ABSTRACT
Background. Acute kidney injury (AKI) diagnosis requires ascertainment of change from a known baseline. Although pre-
admission serum creatinine (SCr) is recommended, to date, all studies of AKI in acute stroke have used the first SCr on
admission.
Methods. All patients admitted with an acute stroke to an emergency hospital were recruited. We compared use of pre-
admission SCr with admission SCr to diagnose AKI. Regression analyses were used to identify risk factors for 30-day and 1-
year mortality, respectively.
Results. A total of 1354 patients were recruited from December 2012 to September 2015. Incidence of AKI was 18.7 and 19.9%
using pre-admission SCr and admission SCr, respectively. Diagnosis of AKI was associated with significantly increased 30-day
and 1-year mortality. Diagnosis of AKI using pre-admission SCr had a stronger relationship with both 30-day and 1-year
mortality. In 443 patients with a pre-admission SCr and at least two SCr during admission, AKI diagnosed using pre-admission
SCr had a stronger relationship than AKI diagnosed using admission SCr with 30-daymortality [odds ratio (OR) ¼ 2.64; 95%
confidence interval (CI) 1.36–5.12; P ¼ 0.004 versus OR¼ 2.10; 95% CI 1.09–4.03; P ¼ 0.026] and 1-year mortality [hazard ratio (HR)
¼ 1.90, 95% CI 1.32–2.76; P ¼ 0.001 versus HR¼ 1.47; 95% CI 1.01–2.15; P ¼ 0.046] in fully adjustedmodels.
Conclusions. AKI after stroke is common and is associated with increased 30-day and 1-year mortality. Using first SCr on
admission gives a comparable AKI incidence to pre-admission SCr, but underestimates 30-day and 1-year mortality risk.
Keywords: acute kidney injury, mortality, stroke
INTRODUCTION
There is wide variation in the reported incidence of acute kid-
ney injury (AKI) depending on definitions and populations stud-
ied: from 5.4% to 18.3% [1, 2] for hospitalized patients, to 40% in
patients requiring intensive care [3, 4]. Having an episode of AKI
is associated with increased mortality, inpatient length of stay
and healthcare costs [5], and confers a higher risk of developing
chronic kidney disease (CKD) [6] with its own sequelae.
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Currently, AKI diagnosis relies on the ascertainment of a peak
increase in SCr from a known ‘baseline’ value [7]. The Acute
Kidney Injury Network (AKIN) [8, 9] and European Renal Best
Practice (ERBP) guideline [10] recommend the use of first SCr on
admission. Kidney Disease: Improving Global Outcomes (KDIGO)
recommends that AKI diagnosis requires knowledge of change in
SCr from a known ‘baseline’ [7]. A developing consensus favours
the use of an average SCr 7–365days up to admission [8, 9, 11–15].
Stroke is the second most common cause of death and the
leading cause of neurological disability worldwide [16]. Patients
suffering a stroke are typically older, have significant co-
morbidities and often have associated CKD [17, 18]. All of these
features are recognized to be associated with AKI [3]. However,
a recent systematic review and meta-analysis highlighted the
fact that risk factors for AKI after a stroke have not been exten-
sively investigated, and most studies have confined themselves
to known generic risk factors for AKI [19]. Only two studies ex-
amined the association between stroke severity and AKI and
only one study investigating the relationship between radiologi-
cal contrast exposure and development of AKI [19].
Furthermore, no study has examined the association between
thrombolysis, angiographic procedures or vascular interven-
tions after an ischaemic stroke [19]. With an ageing population
and increasing prevalence of CKD, together with an increasing
use of interventional procedures, it is important to establish
risk factors for, and the true incidence of, AKI after a stroke in
order to design studies to potentially improve outcomes.
To date, all studies investigating AKI in acute stroke have used
the first SCr result on admission [20–22]. No study has investigated
the use of different methods to classify AKI and their relationship
to outcomes in acute stroke. To address this, we sought to deter-
mine in a population of patients admitted with an acute stroke:
i. the incidence of AKI determined using pre-admission SCr
compared with first SCr on admission;
ii. the risk factors for AKI in stroke patients; and
iii. the impact of AKI on mortality at 30 days and 1 year using
different methods for AKI diagnosis.
MATERIALS ANDMETHODS
Study design and population
This was a prospective cohort study of patients presenting with
an acute stroke (acute ischaemic stroke or intracranial haemor-
rhage) between December 2012 and September 2015 to an acute
hospital in UK. Readmissions and patients with end-stage renal
disease (ESRD) were excluded. A stroke physician assessed each
case by history, neurological examination and brain imaging
(computerized tomography and/or magnetic resonance imag-
ing). We followed the STrengthening the Reporting of
OBservational studies in Epidemiology guidelines [23].
Data collection and follow-up period
We used data from the Sentinel Stroke National Audit
Programme [24]. Demographic data including age, sex, ethnicity,
Index of Multiple Deprivation score, comorbidities [hyperten-
sion, diabetes mellitus, congestive heart failure, previous stroke
or transient ischaemic attack (TIA) and atrial fibrillation (AF)]
and stroke type were extracted from the database. Degree of
disability was determined using the modified Rankin scale [25]
and stroke severity using the National Institutes of Health
Stroke Scale score [26]. Mortality data up to 1year were collected
from the Office of National Statistics [27]. Pre-admission SCr
was calculated as the mean of all pre-admission SCr values 7–
365days before admission [15].
Impaired renal function was defined as an estimated glomeru-
lar filtration rate (eGFR) of <60 mL/min/1.73 m2 using the Chronic
Kidney Disease Epidemiology Collaboration and subdivided into
GFR categories as per KDIGO CKDGuidelines [28]. For patients with
no pre-admission SCr, impaired renal function was defined as an
eGFR <60mL/min/1.73 m2 using the first SCr value on admission.
Anaemia was defined as a haemoglobin level <135g/L for males
and<115g/L for females as per laboratory reference ranges.
Patients were divided into three groups depending on the
availability of SCr data (Figure 1): Group A: all patients with at
least one pre-admission SCr available in the 7–365days preced-
ing admission; Group B: all patients with at least two SCr avail-
able after admission; and Group C: all patients that that fulfilled
criteria for Groups A and B. Patients could therefore be assigned
to more than one group.
Ethical approval was granted for this study (East of England–
Essex Research Ethics Committee 16/EE/0166).
Definition of AKI
The rate of AKI using pre-admission SCr (termed AKIpre) was
compared with the surrogate, first SCr on hospital admission
(termed AKIadm). AKI was defined as per KDIGO guidelines [7].
Urine output criteria were not used since electronic records of
urine output were incomplete.
Statistical analysis
Analyses were performed using SPSS 24.0 (SPSS Inc., Chicago, IL,
USA). Continuous variables are expressed as mean 6standard
deviation (SD) for normally distributed variables or median and
interquartile range for non-normally distributed variables and
compared using the t-test or Mann–Whitney U test. Categorical
variables are expressed as proportions and compared using the
Chi-squared test or McNemar test for dichotomous variables
[29]. All variables used in the analysis had <5% of values miss-
ing and were therefore treated as missing completely at random
with case-wise deletion.
AKIpre and AKIadm methods were compared using the Bland–
Altman method [30]. Sensitivity and specificity were reported
for each method with the kappa value and 95% confidence
intervals (CIs) used to denote the level of agreement between
different methods. We calculated misclassification rates as the
proportion of patients incorrectly assigned as having AKI as
compared with AKIpre and compared correctly classified and
misclassified AKI using the McNemar test.
Kaplan–Meier survival curves were drawn to assess group
differences for time-to-event data and compared using the Log
rank test. Logistic regression was used to assess the relationship
between outcomes and parameters under investigation,
expressed as an odds ratio (OR) with 95% CI. Time-to-event
analysis for cumulative 1-year mortality was performed using
the Cox proportional hazards model and results expressed as a
hazard ratio (HR) with 95% CI. Variables found to be associated
with the outcome under investigation in the univariable analy-
sis were included in the multivariable models. A P-value thresh-
old of <0.15 was selected in order to retain all potential risk
factors and minimize the chance of type II errors [31].
RESULTS
In total, 1440 hospital admissions with acute stroke occurred
within the study period (Figure 1). From these, 52 patients who
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were readmitted over the same period were excluded, as well as
13 duplicates and 21 patients with ESRD. The remaining 1354
patients were included for analysis. Among these patients, 725
(53.5%) fulfilled criteria for inclusion in Group A, 808 (59.7%) for
Group B and 443 (32.7%) for Group C.
Characteristics of patients with and without
pre-admission SCr
The baseline characteristics of the study population with and
without pre-admission SCr data are shown in Table 1. In multi-
variable analysis, patients with pre-admission SCr values were
more likely to be older, of non-Black ethnicity, have a concur-
rent diagnosis of diabetes mellitus, AF, previous stroke or TIA,
and have higher disability on admission (Supplementary data,
Appendix S1).
AKI diagnosis
Rates of AKI using AKIpre and AKIadm were compared in patients
in Group C. There was no difference in the rates of AKI using
AKIpre or AKIadm (18.7% versus 19.9%; P¼ 0.63). The rates of AKI
and agreement between methods are summarized in
Supplementary data, Appendix S2. The overall misclassification
rate was 17.4% (Kappa statistic 0.46 with 9.7% of cases overclas-
sified and 7.7% of cases underclassified as having AKI)
(Supplementary data, Appendix S3). A Bland–Altman plot
(Supplementary data, Appendix S4) showed the majority of val-
ues fall within the limits of agreement.
Comparison of pre-admission SCr and admission SCr
In Group C, 25.1% had a first admission SCr that was 110%
above the pre-admission SCr (Supplementary data, Appendix
S5). A greater proportion of patients classified as having AKIpre
experienced this pattern compared with patients classified as
having AKIadm (48.2 and 20.5%, respectively). Conversely, 23.9%
had a first admission SCr that was 90% of the pre-admission
SCr with a greater proportion of patients with AKIadm compared
with AKIpre experiencing this pattern (33.0 and 12.0%,
respectively). Similar results were obtained in Group A
(Supplementary data, Appendix S6).
Factors associated with AKI
In Group C, factors associated with AKIpre and AKIadm in multi-
variable analyses (Supplementary data, Appendix S7) were the
presence of an eGFR <60mL/min/1.73 m2 (OR ¼ 2.78; 95% CI
FIGURE 1: Study flow diagram. SSNAP, Sentinel Stroke National Audit Programme.
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1.69–4.57; P<0.001 and OR ¼ 2.60; 95% CI 1.60–4.23; P< 0.001, re-
spectively) and anaemia (OR ¼ 1.78; 95% CI 1.06–2.97; P¼ 0.03
and OR ¼ 1.96; 95% CI 1.19–3.24; P¼ 0.009, respectively). Similar
associations were found in Group A for AKIpre (Supplementary
data, Appendix S8) and in Group B for AKIadm (Supplementary
data, Appendix S9).
AKI and 30-day mortality
In Group A, 30-day mortality was significantly higher in patients
with AKIpre compared with patients without AKI [(24/88) 27.3%
versus (66/637) 10.5%; P<0.001]. In Group B, the mortality rate
was also higher in the AKIadm group [(27/134) 20.1% versus (82/
674) 12.2%; P¼ 0.01]. In Group C, mortality was higher in the AKI
group when both AKIpre [(24/83) 28.9% versus (50/360) 13.9%;
P¼ 0.001] and AKIadm [(21/88) 23.9% versus (53/355) 14.9%;
P¼ 0.04] were used to identify AKI compared with patients with-
out AKI.
The full univariable and multivariable associations with 30-
day mortality in Groups A and B are shown in Supplementary
data, Appendices S10 and S11. In Group A, AKIpre was associated
with 30-day mortality in multivariable analysis (OR ¼ 2.66; 95%
CI 1.40–5.05; P¼ 0.003; Table 2). In Group B, AKIadm was associ-
ated with 30-day mortality in multivariable analysis (OR ¼ 1.79;
95% CI 1.04–3.08; P¼ 0.04; Table 2).
The full univariable and multivariable associations with 30-
day mortality in Group C are shown in Supplementary data,
Appendix S12. Both AKIpre (OR ¼ 2.64; 95% CI 1.36–5.12; P¼ 0.004)
and AKIadm (OR ¼ 2.10; 95% CI 1.09–4.03; P¼ 0.03) remained asso-
ciated with 30-day mortality in the adjusted models (Table 2).
Given that AKIpre appeared to have a stronger relationship with
30-day mortality than AKIadm, we constructed further models
adjusting for factors associated with 30-day mortality when ei-
ther AKIpre or AKIadm were used in the multivariable model. The
OR for mortality remained higher using AKIpre than AKIadm in
all models (Models 3–5; Table 2). We created additional models
by entering both AKIpre and AKIadm. In all models, only AKIpre
was retained (Models 6–10; Table 2), suggesting that AKIpre does
indeed have a stronger relationship with 30-day mortality than
AKIadm. We further explored this relationship by forcing AKIadm
into the multivariable models and then adding AKIpre. In all
cases, AKIpre was also retained in the models, suggesting that
AKIpre carries further information than that provided by AKIadm
alone (Models 11–15; Table 2).
AKI and 1-year mortality
In Group A, 1-year mortality was significantly higher in patients
with AKIpre compared with patients without AKI [(42/88) 47.7%
versus (131/637) 20.8%; P<0.001]. In Group B, the mortality rate
was higher in the AKIadm group [(51/134) 38.1% versus (156/674)
23.1%; P<0.001]. In Group C, mortality was higher in the AKI
group when both AKIpre [(42/83) 50.6% versus (97/360) 26.9%;
P<0.001] and AKIadm [(38/88) 43.2% versus (101/355) 28.5%;
P<0.001] were used to identify AKI compared with patients
without AKI (Figure 2).
The full univariable and multivariable associations with 1-
year mortality in Groups A and B are shown in Supplementary
data, Appendices S13 and S14. In Group A, AKIpre was associated
with 1-year mortality in multivariable analysis (HR ¼ 2.00; 95%
CI 1.40–2.86; P<0.001; Table 3). In Group B, AKIadm was associ-
ated with 1-year mortality in multivariable analysis (HR ¼ 1.50;
95% CI 1.10–2.07; P¼ 0.01; Table 3).
The full univariable and multivariable associations with 1-
year mortality in Group C are shown in Supplementary data,
Table 1. Baseline characteristics according to presence of pre-admission SCr
Parameters With pre-admission SCr (n¼ 725) Without pre-admission SCr (n¼ 629)
Age, years, mean (SD) 74.83 (14.09) 69.04 (16.33)
Male (%) 366 (50.5) 362 (57.6)
Ischaemic stroke (%) 643 (88.7) 553 (87.9)
NIHSS score on admission, median (IQR) 3.0 (8) 4.0 (8)
NIHSS level of consciousness (0–3), median (IQR) 0 (0) 0 (0)
IMD score, mean (SD) 30.51 (15.37) 30.60 (17.82)
Ethnic group (%)
White 625 (86.2) 505 (80.3)
Asian/Asian British 68 (9.4) 61 (9.7)
Black/Black British 18 (2.5) 32 (5.1)
Mixed/other/unknown 14 (1.9) 31 (4.9)
Pre-admission SCr, mean (SD) (mmol/L) 91.32 (31.40) –
Pre-admission eGFR, mean (SD) (mL/min/1.73 m2) 68.45 (22.72) –
Admission SCr, mean (SD) (mmol/L) 91.15 (41.55) 84.14 (24.78)
Admission eGFR, mean (SD) (mL/min/1.73 m2) 67.90 (22.71) 75.84 (22.35)
Pre-admission eGFR <60 mL/min/1.73 m2 (%) 278 (38.3) –
Admission eGFR <60 mL/min/1.73 m2 (%) 275 (37.9) 159 (25.3)
Hypertension (%) 378 (52.1) 273 (43.4)
Diabetes mellitus (%) 175 (24.1) 105 (16.7)
CHF (%) 35 (4.8) 17 (2.7)
Previous stroke/TIA (%) 218 (30.1) 122 (19.4)
AF (%) 179 (24.7) 75 (11.9)
Thrombolysis (%) 64 (8.8) 105 (16.7)
Thrombectomy (%) 14 (1.9) 38 (6.0)
Any iodinated contrast exposure (%) 130 (17.9) 151 (24.0)
Data are presented as mean6SD, median (IQR) or n (%).
CHF, congestive heart failure; IMD, Index of Multiple Deprivation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale.
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Appendix S15. Both AKIpre (HR ¼ 1.90; 95% CI 1.32–2.76;
P¼ 0.001) and AKIadm (HR ¼ 1.47; 95% CI 1.01–2.15; P¼ 0.05)
remained associated with 1-year mortality in the adjusted
models (Table 3). Similar to 30-day mortality, AKIpre appeared
to have a stronger relationship with 1-year mortality than
AKIadm, and further models were constructed adjusting for fac-
tors associated with 1-year mortality when either AKIpre or
AKIadm were used in the multivariable model (Table 3). The HR
for mortality remained higher using AKIpre than AKIadm in all
models (Models 3–5; Table 3). We created additional models by
entering both AKIpre and AKIadm. In all models, only AKIpre was
retained (Models 6–10; Table 3), suggesting AKIpre does indeed
have a stronger relationship with 30-day mortality than
AKIadm. We further explored this relationship by forcing
AKIadm into the multivariable models and then adding AKIpre.
In all cases, AKIpre was also retained in the models, suggesting
that AKIpre carries further information than that provided by
AKIadm (Models 11–15; Table 3).
DISCUSSION
To the best of our knowledge, this is the first study to investi-
gate the rate of AKI in acute stroke utilizing two different meth-
ods. We show that AKI in unselected patients hospitalized after
a stroke is high at 20% and this rate does not appear to be de-
pendent on the method used to diagnose AKI. We also show
that mortality after AKI is high but consistently higher in AKIpre,
with 27.3 and 47.7% of patients being dead at 30 days and 1 year,
respectively. Use of AKIadm consistently underestimates mortal-
ity risk at both time points.
SCr is an imperfect measurement of dynamic glomerular
filtration rate [32] and is modified by age, sex and race as well as
nutritional state, muscle mass and hydration [3]. Consequently,
novel biomarkers for earlier and more accurate detection of AKI
are under investigation, but to date, these have not progressed to
use in routine medical practice [33–36]. Therefore, SCr remains
the only routinely used laboratory test for the diagnosis of AKI
[37–39].
Table 2. Logistic univariable and multivariable associations of AKI calculated using pre-admission SCr (AKIpre) or admission creatinine
(AKIadm) with 30-day mortality
Models
Group A (AKIpre) Group B (AKIadm) Group C (AKIpre) Group C (AKIadm)
OR P-value OR P-value OR P-value OR P-value
Model 1 3.21 <0.001 1.82 0.015 2.52 0.001 1.79 0.046
(1.88–5.48) (1.13–2.95) (1.44–4.42) (1.01–3.16)
Model 2 2.86 <0.001 1.58
(0.96–2.60)
0.07 2.37 0.003 1.71
(0.95–3.07)
0.07
(1.65–4.98) (1.33–4.22)
Model 3 2.66 0.003 1.79 0.04 2.64 0.004 2.10 0.03
(1.40–5.05) (1.04–3.08) (1.36–5.12) (1.09–4.03)
Model 4 2.66 0.003 1.79 0.04 2.64 0.004 2.10 0.03
(1.40–5.05) (1.04–3.08) (1.36–5.12) (1.09–4.03)
Model 5 2.66 0.003 1.79 0.04 2.64 0.004 2.10 0.03
(1.40–5.05) (1.04–3.08) (1.36–5.12) (1.09–4.03)
Model 6 – – – – 2.52 0.001
(1.44–4.42)
Model 7 – – – – 2.37 0.003
(1.33–4.22)
Model 8 – – – – 2.64 0.004
(1.36–5.12)
Model 9 – – – – 2.64 0.004
(1.36–5.12)
Model 10 – – – – 2.64 0.004
(1.36–5.12)
Model 11 – – – – AKIadm 1.13 (0.57–2.25) 0.73 – –
AKIpre 2.37 (1.21–4.62) 0.01
Model 12 – – – – AKIadm 1.09 (0.54–2.22) 0.81 – –
AKIpre 2.323 (1.160–4.650) 0.02
Model 13 – – – – AKIadm 1.35 (0.61–3.01) 0.46 – –
AKIpre 2.20 (1.00–4.84) 0.051
Model 14 – – – – AKIadm 1.38 (0.62–3.10) 0.43 – –
AKIpre 2.22(1.00–4.91) 0.049
Model 15 – – – – AKIadm 1.35 (0.60–3.02) 0.47 – –
AKIpre 2.25 (1.02–4.97) 0.046
Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: adjusted for age, sex, presence of eGFR <60 mL/min/1.73 m2 and AF, stroke type, disability score on ad-
mission, stroke severity and anaemia (all factors associated in univariable analysis with 30-day mortality in Group A). Model 4: adjusted for age, sex, ethnicity, presence
of eGFR <60 mL/min/1.73 m2, AF and hypertension, disability score on admission, stroke severity and anaemia (all factors associated in univariable analysis with 30-
day mortality in Group B). Model 5: adjusted for age, sex, ethnicity, presence of eGFR <60 mL/min/1.73 m2, AF and hypertension, stroke type, disability score on admis-
sion, stroke severity and anaemia (all factors associated in univariable analysis with 30-day mortality in Groups A and B). Model 6: Model 1þAKIpre and AKIadm. Model
7: Model 2þAKIpre and AKIadm. Model 8: Model 3þAKIpre and AKIadm. Model 9: Model 4þAKIpre and AKIadm. Model 10: Model 5þAKIpre and AKIadm. Model 11: Model 6
with AKIadm forced into model. Model 12: Model 7 with AKIadm forced into model. Model 13: Model 8 with AKIadm forced into model. Model 14: Model 9 with AKIadm
forced into model. Model 15: Model 10 with AKIadm forced into model.
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Use of admission SCr, as recommended by AKIN [8, 9] and
ERBP guidelines [10], to diagnose AKI has low sensitivity and may
therefore fail to detect both community-acquired and hospital-
acquired AKI [40]. Use of a baseline SCr taken 7–365days up to ad-
mission [8, 9, 11–15] is not available for many patients because of
the absence of a pre-admission value. In our cohort, 46.5% of
patients did not have a pre-admission SCr, consistent with pub-
lished data [41], and we found that patients with a pre-admission
SCr were more likely to be older and have more comorbidities.
Although we have performed several analyses to exclude this as
a major source of confounding, it remains possible that some re-
sidual confounding persists and our findings require confirma-
tion in other studies. Patients of black ethnicity were less likely to
have a pre-admission SCr, consistent with reports that this eth-
nic group is less likely to have access to health systems both in
the USA and the UK [42–44]. This has partly been attributed to
socioeconomic status [45]. However, in this study, socioeconomic
deprivation did not appear to be associated with having a pre-ad-
mission SCr. It is uncertain whether this is a factor of the UK’s so-
cial system of healthcare or whether it would be replicated in
other healthcare systems [44].
Using admission SCr to diagnose AKI in our cohort produced
a similar rate of AKI to pre-admission SCr. These rates are com-
parable to other published studies that utilize SCr values rather
than coding to diagnose AKI, with rates ranging from 15% to
27% [20–22]. However, although the absolute rates are similar,
AKIadm when compared with AKIpre had low sensitivity and a
Kappa value indicating only moderate agreement. We also
found that individual patients were just as likely to have a SCr
on admission that was 10% higher or 10% lower than the pre-
admission SCr. This could potentially suggest a random effect
consistent with day-to-day biological fluctuations in SCr [46, 47]
FIGURE 2: (A) Kaplan–Meier survival curve at 365days for Group C using AKIpre to diagnose AKI rates. Log rank test ¼ 19.73; P < 0.001. (B) Kaplan–Meier survival curve
for Group C at 365days using AKIadm to diagnose AKI. Log rank test ¼ 6.93; P ¼ 0.008.
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or analytical variability in the laboratory [48]. Consistent with
this, we found that patients with a higher admission SCr were
more likely to be diagnosed with AKIpre, whereas patients with
a lower admission SCr were more likely to be diagnosed with
AKIadm. Despite the similar rates of AKI diagnosed with either
method, we found that AKIpre was consistently associated with
higher 30-day and 1-year mortality than AKIadm. Although we
cannot prove this conclusively, our results would suggest that
using AKIpre correctly identifies more patients with ‘true’ AKI.
Furthermore, our finding that AKIpre was associated with a
higher mortality risk than AKIadm indicates that AKI-associated
mortality in acute stroke, as reported to date, probably underes-
timates the association, given that all of the studies that used
SCr to define AKI used first SCr on admission [20–22]. These
findings have major implications for clinical management and
further research. Future epidemiological, or indeed interven-
tional studies, should make every effort to use pre-admission
SCr as the baseline for AKI diagnosis.
In some clinical situations, where the first SCr on admission
is taken as the baseline value, cases of community-acquired
AKI may be missed, thus underestimating AKI incidence [8].
Conversely, in older and frailer patients with an acute illness,
the admission SCr may be lower than the outpatient ‘baseline’,
leading to overestimation of AKI rates [14, 49]. Inclusion of
patients without true AKI in the analysis may introduce further
bias. This was emphasized by a recent US study which reported
that 45% of all hospitalized patients had a first SCr on admission
<90% of the pre-admission SCr [14]. However, we feel that these
are unlikely to have been significant factors in our study. Acute
stroke, by its very nature, happens suddenly and patients are
usually admitted to hospital almost immediately, giving little
time to develop community-acquired AKI. Patients presenting
with a first acute stroke might also be less likely to have a grad-
ually worsening health state preceding the admission, and
therefore less likely to have a lower SCr as might be expected in
patients with more chronic conditions.
Our study has some limitations to acknowledge. A signifi-
cant proportion of the cohort had no pre-admission SCr. This
may have caused confounding since patients with available
pre-admission SCr likely represent a more comorbid group. To
Table 3. Cox univariable and multivariable associations of AKI calculated using pre-admission SCr (AKIpre) or admission creatinine (AKIadm)
with 1 year mortality
Models
Group A (AKIpre) Group B (AKIadm) Group C (AKIpre) Group C (AKIadm)
HR P-value HR P-value HR P-value HR P-value
Model 1 2.74 <0.001 1.77 <0.001 2.22 <0.001 1.64 0.009
(1.937–3.886) (1.29–2.42) (1.55–3.19) (1.13–2.38)
Model 2 2.43 <0.001 1.52 0.009 2.08 <0.001 1.55 0.02
(1.72–3.45) (1.11–2.09) (1.44–2.99) (1.07–2.26)
Model 3 2.00 <0.001 1.50 0.01 1.98 <0.001 1.53 0.03
(1.40–2.86) (1.10–2.07) (1.37–2.85) (1.05–2.23)
Model 4 2.00 <0.001 1.50 0.01 1.98 <0.001 1.53 0.03
(1.40–2.86) (1.10–2.07) (1.37–2.85) (1.05–2.23)
Model 5 2.00 <0.001 1.50 0.01 1.90 0.001 1.47 0.05
(1.40–2.86) (1.10–2.07) (1.32–2.76) (1.01–2.15)
Model 6 – – – – 2.22 <0.001
(1.55–3.19)
Model 7 – – – – 2.08 <0.001
(1.44–2.99)
Model 8 – – – – 1.98 <0.001
(1.37–2.85)
Model 9 – – – – 1.98 <0.001
(1.37–2.85)
Model 10 – – – – 1.90 0.001
(1.32–2.76)
Model 11 – – – – AKIadm 1.11 (0.71–1.74) 0.65 – –
AKIpre 2.10 (1.36–3.25) 0.001
Model 12 – – – – AKIadm 1.07 (0.68–1.66) 0.78 – –
AKIpre 2.06 (1.33–3.18) 0.001
Model 13 – – – – AKIadm 1.09 (0.69–1.72) 0.70 – –
AKIpre 2.02 (1.29–3.17) 0.002
Model 14 – – – – AKIadm 1.07 (0.68–1.70) 0.76 – –
AKIpre 1.96 (1.25–3.08) 0.004
Model 15 – – – – AKIadm 1.06 (0.67–1.68) 0.81 – –
AKIpre 2.00 (1.27–3.16) 0.003
Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: adjusted for age, sex, presence of eGFR <60 mL/min/1.73 m2, AF and CHF, stroke type, disability score
on admission, stroke severity and anaemia (all factors associated in univariable analysis with 1-year mortality in Group A). Model 4: adjusted for age, sex, presence of
eGFR <60 mL/min/1.73 m2 and AF, disability score on admission, stroke severity and anaemia (all factors associated in univariable analysis with 1-year mortality in
Group B). Model 5: Model 3 plus ethnicity. Model 6: Model 1þAKIpre and AKIadm. Model 7: Model 2þAKIpre and AKIadm. Model 8: Model 3þAKIpre and AKIadm. Model 9:
Model 4þAKIpre and AKIadm. Model 10: Model 5þAKIpre and AKIadm. Model 11: Model 6 with AKIadm forced into model. Model 12: Model 7 with AKIadm forced into
model. Model 13: Model 8 with AKIadm forced into model. Model 14: Model 9 with AKIadm forced into model. Model 15: Model 10 with AKIadm forced into model.
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address this, we selected a core cohort of patients (Group C)
who had both a pre-admission SCr value and at least two blood
tests during admission and used multiple adjustments in our
analysis. However, it is possible that residual confounding
remains. We do not have data on the length of time between
the onset of the acute stroke and the drawing of blood for mea-
surement of SCr. However, patients suffering an acute stroke
are generally admitted to hospital immediately and blood
drawn shortly after arrival in the emergency department.
Therefore, the interval is unlikely to be ever more than a few
hours and it is doubtful that this would have a significant effect
on the findings. We do not have data on cause of death. There is
surprisingly little data on the cause of death after AKI. A recent
population-based study has shown that the most common
causes of death after AKI are cancer or cardiovascular events
[50]. We would therefore predict that cardiovascular events
were the most common cause of death after AKI in stroke
patients, but further work is required to prove this. Our study
utilizes data from a cohort of stroke patients and therefore AKI
incidence, risk factors and outcomes may be different to an un-
selected hospital population with AKI. Finally, we were limited
by the observational nature of this study and were unable to ad-
dress causality.
CONCLUSIONS
In summary, AKI after stroke is common and associated with
increased mortality. First creatinine on admission gives a com-
parable incidence of AKI to pre-admission creatinine but with
low sensitivity. First creatinine on admission to classify AKI
consistently underestimates 30-day and 1-year mortality com-
pared with pre-admission SCr. Further studies are required to
help inform future AKI prevention trials that are urgently
needed to ultimately improve clinical outcomes.
SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
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